NCT07173348Recruiting
Hypnosis on Breathlessness Mastery in Patients With Persistent Dyspnea
Effectiveness of Hypnosis on Breathlessness Mastery in Patients With Persistent Dyspnea: a Randomised Controlled Trial
Source: ClinicalTrials.gov · Last updated 8 Jun 2026
Brief summary (registry, in English)
Persistent dyspnea is a debilitating symptom, that is common and difficult to treat. This symptom is found in many different diseases including chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), chronic heart failure (CHF), and metastatic cancer. Dyspnea is associated with many other symptoms, including anxiety, depression, and fatigue and is responsible for a significant reduction in quality of life. To date, only opiates are recommended for the pharmacological treatment of persistent dyspnea. The effectiveness of hypnosis is well known in the treatment of anxiety and delivered to patients suffering from chronic dyspnea for this reason. One randomised controlled study has shown that a single 20-minute mindfulness sessions could significantly reduce general symptom burden and have a significant impact on anxiety and depression in palliative care patients. Furthermore, the intervention had no negative side effects. Our aim is to evaluate the effectiveness of three hypnosis sessions on breathlessness mastery in patients with persistent dyspnea, using as a primary outcome the mastery domain of a validated tool, the Chronic Respiratory Questionnaire (CRQ).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 82 (estimated)
- First submitted
- 26 Aug 2025
- Start date
- 1 Apr 2026
- Primary completion date
- 1 Feb 2028
- Lead sponsor
- University Hospital, Geneva
- Diseases
- Heart failure, COPD
- NCT number
- NCT07173348
What you commit to
- Study type: Interventional
- Planned participants: 82
- From 1 Apr 2026 to the primary completion date, 1 Feb 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Have a condition that would interfere with their ability to respond to the questionnaires (i.e. cognitive impairment, hearing impairment, etc.)
- Are not eligible for a hypnosis session due to a psychiatric disorder
Other
- Have had hypnosis treatment in the last 12 months
- Have an estimated life expectancy of less than 6 months
- Have participated in pulmonary rehabilitation in the last 6 months
- Have been hospitalised in the last month (30 days)
- Are unable to come to the hospital for 3 outpatient consultations (1 every two weeks)
Who the study is looking for
- Patients aged ≥ 18 years and
- Primary diagnosis of metastatic cancer, COPD stage at least B or E, ILD, or CHF and
- Dyspnea stage NYHA ≥ II or mMRC ≥ 2
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Geneva University Hospitals Coordinator of this site? Confirm its status | Geneva | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.